Indoco holds a strong foothold across various therapeutic categories including Gastroenterology, Dentistry, Respiratory, Diabetology, and Women's Health, with domestic business crossing 1,280 Cr in FY24, ranking 31st in India. The company presents a balanced business model positioned to benefit from India's growing healthcare ecosystem driven by higher spending, population growth, and rising disease burden.
Cyborg Score Rationale
The company has delivered poor sales growth of 8.51% over past five years. Modest R&D limits innovation, risking future growth and weakening competitiveness in complex drug markets. However, recent USFDA approvals for Lacosamide Oral Solution demonstrate ongoing regulatory progress.
Top Insights
Domestic formulations segment represents 48% of FY24 revenue with 31st ranking in Indian market among 240,000+ prescribers
Recent family succession planning: Kare Family Pvt. Trust acquired 51.3% voting rights in late 2025
Recent USFDA approvals (Lacosamide Oral Solution) and API facility EIR compliance indicate regulatory progress in US market
Stock trading at 43.9% discount to fair value estimate per analyst consensus, but negative earnings pressure and 8.51% five-year revenue growth
Named Competitors
Sun Pharma — Larger multinational generics competitor
Cipla — Major Indian generic pharmaceutical manufacturer
Dr Reddy's — Leading Indian pharma with stronger R&D capabilities
Recent Developments
(January 2026) USFDA nod for Lacosamide Oral Solution (Vimpat generic) manufactured at Goa plant
(December 2025) Indoco Remedies API facility at Patalganga received USFDA EIR confirming compliance
(December 2025) Kare Family Pvt. Trust acquired 51.3% voting rights; management succession planning underway